CIK 0001326190 · Non-accelerated filer<br>Smaller reporting company
Altimmune, Inc.
Sign in to watch- Ticker
- ALT
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 202726770
- Phone
- 862-457-1450
- Business address
- 350 MOUNT KEMBLE AVENUE, SUITE 1001, MORRISTOWN, NJ, 07960
- Former names
- PHARMATHENE, INC, HEALTHCARE ACQUISITION CORP
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2019-01-02 | Drutz David Director | Grant or award · Stock Options (option to buy) | +20,000 | 20,000 | ||
| 2019-01-02 | Pisano Wayne Director | Grant or award · Stock Options (option to buy) | +20,000 | 20,000 | ||
| 2019-01-02 | Tasker Sybil Chief Medical Officer | Grant or award · Stock Options (option to buy) | +30,000 | 30,000 | ||
| 2019-01-02 | Roberts M Scot Chief Scientific Officer | Grant or award · Stock Options (option to buy) | +30,000 | 30,000 | ||
| 2018-11-30 | Garg Vipin K President and CEO | Grant or award | +322,907 | 322,907 | ||
| 2018-11-30 | Garg Vipin K President and CEO | Grant or award · Stock Options (option to buy) | +211,486 | 211,486 | ||
| 2018-11-30 | Garg Vipin K President and CEO | Grant or award · Stock Options (option to buy) | +111,421 | 111,421 | ||
| 2018-10-09 | Pisano Wayne Director | Purchase | +2,000 | $4.59 | $9K | 2,000 |
| 2018-09-12 | Novartis Bioventures Ltd 10% owner | Other acquisition | +2,069,993 | 8,345,145 | ||
| 2018-09-12 | Novartis Bioventures Ltd 10% owner | Other disposition · Warrants | −465,086 | 0 | ||
| 2018-07-11 | Novartis Bioventures Ltd 10% owner | Other acquisition | +663,346 | 6,275,152 | ||
| 2018-07-11 | Novartis Bioventures Ltd 10% owner | Other disposition · Series B Convertible Preferred Stock | −344.93 | $940.00 | $324K | 0 |
| 2018-06-15 | Novartis Bioventures Ltd 10% owner | Other acquisition | +14,449 | 5,611,806 | ||
| 2018-06-13 | Novartis Bioventures Ltd 10% owner | Other acquisition | +720,878 | 5,597,357 | ||
| 2018-06-13 | Novartis Bioventures Ltd 10% owner | Other disposition · Series B Convertible Preferred Stock | −344.94 | 344.93 | ||
| 2018-05-25 | Enright William President and CEO | Purchase | +1,300 | $0.51 | $660 | 365,839 |
| 2018-05-21 | Tasker Sybil Chief Medical Officer | Grant or award · Stock Options (option to buy) | +50,016 | 50,016 | ||
| 2018-05-21 | Roberts M Scot Chief Scientific Officer | Option exercise | +55,120 | $0.08 | $4K | 55,120 |
| 2018-05-21 | Roberts M Scot Chief Scientific Officer | Grant or award · Stock Options (option to buy) | +50,016 | 50,016 | ||
| 2018-05-21 | Roberts M Scot Chief Scientific Officer | Option exercise · Stock Options (option to buy) | −55,120 | 0 |
Page 25 of 29 · 568 trades